Biovail’s Tramadol ER Still Needs Clinical Trial, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Biovail will undertake a new clinical trial for its extended release tramadol following FDA’s preliminary comments on the company’s response to an “approvable” letter. Biovail expects to submit data from the new clinical trial in late 2005 or early 2006.
You may also be interested in...
Biovail’s Tramadol ER Approved Without Additional Clinical Studies
The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.
Biovail’s Tramadol ER Approved Without Additional Clinical Studies
The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.
Biovail's Orally Disintegrating Tramadol Clears FDA
The company is not deciding on a brand name for tramadol ODT until it establishes a strategic marketing partner. Biovail says it is in late-stage discussions with partners for tramadol ODT and extended-release tramadol, which is "approvable" at FDA.